Results 191 to 200 of about 396,791 (317)

Discovery of <i>N</i>-Acetyltransferase 8-Like (NAT8L) inhibitors based on a <i>N</i>-Acylated (Piperidin-3-ylmethyl)-1,2,4-Oxadiazole Scaffold. [PDF]

ACS Med Chem Lett
Nayeen MJ, Thomas AG, Kundu B, Carlyle E, Hin N, Hin P, Pal A, Paule J, Rais R, Slusher BS, Tsukamoto T.   +10 more
europepmc   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

A deep learning framework (CreoPep) for target-specific design and optimization of conotoxin peptides. [PDF]

Commun Chem
Ge C, Tae HS, Lu L, Zhang Z, Huang Z, An B, Wang Y, Jiang T, Cai W, Chang S, Adams DJ, Yu R.   +11 more
europepmc   +1 more source

Quantitative evaluation of mesenchymal stromal cell immunomodulatory potency and cost-effectiveness of cytokine licensing for translational application

Dehua Liao, Jing Wen, Thomas Ritter, Jiemin Wang   +3 more
openalex   +1 more source

Rapid Infrared Determination of the Potency of Chlorinated Bactericides

, 1971
Frank Spagnolo, J. P. Cestaro
openalex   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum. [PDF]

Nat Commun
Khatua K, Atla S, Coleman D, Blankenship LR, Alugubelli YR, Vulupala V, Guo XS, Xia H, Kalveram BK, Walker DH, Hurst BL, Kumar S, Cho CD, Sharma S, Yang K, Rabie D, Nyalata S, Neuman BW, Xie X, Xu S, Liu WR.   +20 more
europepmc   +1 more source

An Experimental Investigation as to the Potency of Various Disinfectants against Rat-Fleas.

, 1906
W. M. C. Hossack
openalex   +1 more source

The potency of finding a new antimalarial drug from Indonesian sea

, 2010
Murtihapsari Murtihapsari, Ekowati Chasanah   +1 more
openalex   +2 more sources

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source